Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Intertek grows LFL sales but trading mixed

(Sharecast News) - Testing, inspection and certification firm Intertek delivered a mixed trading update on Thursday, with strong underlying growth in the consumer products and corporate assurance divisions tempered by declines elsewhere in the business. Group like-for-like sales were up 1.1% at £1.09bn over the first four months of 2025, rising 4.5% at constant currencies.

Shore Capital analyst Robin Speakman said LFL growth was "consistent with our model overall which is, we believe, below consensus down to the EPS level".

Intertek's largest division, Consumer Products, delivered 4.2% LFL sales growth to £310m, while Corporate Assurance grew sales 5.3% on a LFL basis to £161.8m.

However, LFL sales were down across the World of Energy (-2.4% at £240.1m), Industry and Infrastructure (-0.3% at £273.5m), and Health and Safety (-1.3% at £106.7m).

Chief executive André Lacroix called it a "good start to the year, with strong LFL revenue growth in our higher margin divisions", as he reiterated the company's target of mid-single digit LFL revenue growth for the year.

"Margin progression was robust, reflecting divisional mix, pricing initiatives, operating leverage and productivity improvements. Free cash flow was strong which, combined with our strong balance sheet, enabled us to invest in growth and commence our £350m share buyback programme in March," Lacroix said.

Intertek shares were down 2.9% at 4,780p by 0844 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.